FULC Q2 2025 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$300,000

Operating Income

-$20M

Net Income

-$17M

EPS (Diluted)

$-0.28

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$229M

Total Liabilities

$14M

Stockholders' Equity

$214M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$80M	-100.0%
Gross Profit	-$300,000	$63M	-100.5%
Operating Income	-$20M	$52M	-137.7%
Net Income	-$17M	$55M	-131.2%